Significant reductions in cough frequency in study participants with chronic cough treated with gefapixant.

Wednesday, November 2nd, 2022

A recent pooled study by Smith JA et al. (2021) investigated cough frequency in chronic cough patients treated with gefapixant. Results revealed that “in this pooled analysis, gefapixant 45 mg BID demonstrated significant reductions in 24-hour and awake cough frequency vs placebo, with no increase in serious AEs”.  The VitaloJAK™ was used to measure objective cough frequency in this study. 

Read the full report here.

Significant reductions in cough frequency in study participants with chronic cough treated with gefapixant.

Vitalograph’s expert team of cough analysts and the highly consistent performance of the VitaloJAK continue to provide industry-leading objective cough data across different disease areas. Learn more about our expertise in this area.